Vaxcyte (PCVX) Long-Term Investments (2021 - 2026)

Vaxcyte (PCVX) has reported Long-Term Investments for 6 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments fell 21.5% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (down 21.5% YoY), while the FY2025 annual figure was $881.7 million, down 36.46% from the prior year.
• Long-Term Investments rose to $1.0 billion in Q1 2026 per PCVX's latest filing, from $881.7 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $1.4 billion in Q4 2024 and bottomed at $4.0 million in Q3 2022.
• Historically, Long-Term Investments has averaged $544.1 million across 5 years, with a median of $399.2 million in 2024.
• Annual changes were most pronounced in 2022 — Long-Term Investments tumbled 89.99% — and 2023, when it soared 4138.47%.
• Vaxcyte's Long-Term Investments stood at $26.5 million in 2022, then surged by 512.73% to $162.7 million in 2023, then jumped by 752.93% to $1.4 billion in 2024, then sank by 36.46% to $881.7 million in 2025, then advanced by 13.88% to $1.0 billion in 2026.
• Business Quant data shows PCVX's Long-Term Investments at $1.0 billion in Q1 2026, $881.7 million in Q4 2025, and $959.3 million in Q3 2025.